

# Jung-Hwan Yoon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6763602/publications.pdf>

Version: 2024-02-01

278  
papers

11,952  
citations

26630

56  
h-index

38395

95  
g-index

281  
all docs

281  
docs citations

281  
times ranked

15519  
citing authors

#	ARTICLE	IF	CITATIONS
1	Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. <i>Hepatology</i> , 2022, 76, 492-501.	7.3	26
2	A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil) Tj ETQq0 0 0 rgBT /25erlock 10 Tf 50 69		
3	Prognostic Values of Inflammation-Based Scores and Fibrosis Markers in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. <i>Diagnostics</i> , 2022, 12, 1170.	2.6	7
4	Association of Chronic Hepatitis B Infection and Antiviral Treatment With the Development of the Extrahepatic Malignancies: A Nationwide Cohort Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 3394-3405.	1.6	6
5	Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. <i>Journal of Hepatology</i> , 2022, 77, 967-977.	3.7	25
6	Empirical Treatment With Carbapenem vs Third-generation Cephalosporin for Treatment of Spontaneous Bacterial Peritonitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 976-986.e5.	4.4	13
7	Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. <i>Clinical Cancer Research</i> , 2021, 27, 713-718.	7.0	27
8	Association of Metabolic Risk Factors With Risks of Cancer and All-cause Mortality in Patients With Chronic Hepatitis B. <i>Hepatology</i> , 2021, 73, 2266-2277.	7.3	45
9	Epidemiological and Clinical History of Viral Hepatitis in Korea. <i>Infection and Chemotherapy</i> , 2021, 53, 159.	2.3	8
10	Radiofrequency Ablation Using a Separable Clustered Electrode for the Treatment of Hepatocellular Carcinomas: A Randomized Controlled Trial of a Dual-Switching Monopolar Mode Versus a Single-Switching Monopolar Mode. <i>Korean Journal of Radiology</i> , 2021, 22, 179.	3.4	8
11	Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. <i>Journal of Gastroenterology</i> , 2021, 56, 570-580.	5.1	6
12	Effectiveness of Transarterial Chemoembolization-First Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 587-598.	3.7	1
13	Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 649-658.	8.1	58
14	Systems analysis identifies endothelin 1 axis blockade for enhancing the anti-tumor effect of multikinase inhibitor. <i>Cancer Gene Therapy</i> , 2021, , .	4.6	4
15	Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study. <i>JHEP Reports</i> , 2021, 3, 100361.	4.9	24
16	Switching Monopolar No-Touch Radiofrequency Ablation Using Octopus Electrodes for Small Hepatocellular Carcinoma: A Randomized Clinical Trial. <i>Liver Cancer</i> , 2021, 10, 72-81.	7.7	19
17	No-Touch vs. Conventional Radiofrequency Ablation Using Twin Internally Cooled Wet Electrodes for Small Hepatocellular Carcinomas: A Randomized Prospective Comparative Study. <i>Korean Journal of Radiology</i> , 2021, 22, 1974.	3.4	18
18	Safety, tolerability and antiviral activity of the antisense oligonucleotide bepiroviren in patients with chronic hepatitis B: a phase 2 randomized controlled trial. <i>Nature Medicine</i> , 2021, 27, 1725-1734.	30.7	76

#	ARTICLE	IF	CITATIONS
19	Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 6009.	3.7	9
20	Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1565-1577.	3.7	12
21	The Model to Estimate Survival in Ambulatory Hepatocellular Carcinoma Patients Aids in the Decision for TACE Retreatment. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 370-377.	2.2	0
22	RNA Interference Therapy With ARCA520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection. <i>Hepatology</i> , 2020, 72, 19-31.	7.3	84
23	Novel Model to Predict HCC Recurrence after Liver Transplantation Obtained Using Deep Learning: A Multicenter Study. <i>Cancers</i> , 2020, 12, 2791.	3.7	25
24	Changes in serum fibronectin levels predict tumor recurrence in patients with early hepatocellular carcinoma after curative treatment. <i>Scientific Reports</i> , 2020, 10, 21313.	3.3	4
25	Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2020, 66, 2427-2438.	2.3	3
26	CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. <i>BMC Cancer</i> , 2020, 20, 1001.	2.6	4
27	A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function. <i>BMC Cancer</i> , 2020, 20, 504.	2.6	17
28	Entecavir Plus Pegylated Interferon and Sequential Hepatitis B Virus Vaccination Increases Hepatitis B Surface Antigen Seroclearance: A Randomized Controlled Proof-of-Concept Study. <i>Clinical Infectious Diseases</i> , 2020, 73, e3308-e3316.	5.8	12
29	Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. <i>Gut</i> , 2020, 69, 2214-2222.	12.1	20
30	Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B-related hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1960-1968.	2.8	13
31	Tumor-Stroma Crosstalk Enhances REG3A Expressions that Drive the Progression of Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 472.	4.1	9
32	Radiofrequency ablation using internally cooled wet electrodes in bipolar mode for the treatment of recurrent hepatocellular carcinoma after locoregional treatment: A randomized prospective comparative study. <i>PLoS ONE</i> , 2020, 15, e0239733.	2.5	8
33	Comparisons of Clinical Outcomes between Weekday-Only and Full-Time, 24-Hour/7-Day Coverage Hospitalist Systems. <i>Journal of Korean Medical Science</i> , 2020, 35, e117.	2.5	8
34	Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 328-339.	8.9	32
35	Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2020, 14, 225-231.	2.9	2
36	Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study. <i>Gut and Liver</i> , 2020, 14, 477-485.	2.9	1

#	ARTICLE	IF	CITATIONS
37	Child-Pugh B or C Cirrhosis Increases the Risk for Bleeding Following Colonoscopic Polypectomy. <i>Gut and Liver</i> , 2020, 14, 755-764.	2.9	17
38	Appraisal of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma Classified as Barcelona Clinic Liver Cancer Stage B. <i>Gut and Liver</i> , 2020, 14, 377-386.	2.9	1
39	Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986607.	3.2	21
40	Tumor Marker-Based Definition of the Transarterial Chemoembolization-Refractoriness in Intermediate-Stage Hepatocellular Carcinoma: A Multi-Cohort Study. <i>Cancers</i> , 2019, 11, 1721.	3.7	8
41	Comparison of Models for Tumor Recurrence after Liver Transplantation for the Patients with Hepatocellular Carcinoma: A Multicenter Long-Term Follow-Up Study. <i>Cancers</i> , 2019, 11, 1295.	3.7	11
42	Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data. <i>BMC Cancer</i> , 2019, 19, 523.	2.6	24
43	Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1292.	4.1	32
44	Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2019, 70, 1093-1102.	3.7	107
45	Carbonic anhydrase-IX inhibition enhances the efficacy of hexokinase II inhibitor for hepatocellular carcinoma in a murine model. <i>Journal of Bioenergetics and Biomembranes</i> , 2019, 51, 121-129.	2.3	7
46	First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1696-1707.	9.4	157
47	An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2019, 24, 747-e218.	3.7	72
48	Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MR can help determine the treatment method for HCC. <i>European Radiology</i> , 2019, 29, 3122-3131.	4.5	17
49	Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 23-32.	4.2	62
50	Identification of additional EHMT2 variant associated with the risk of chronic hepatitis B by GWAS follow-up study. <i>Genes and Immunity</i> , 2019, 20, 1-9.	4.1	13
51	Safety and efficacy of lenvatinib by starting dose (8 mg or 12 mg) based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.. <i>Journal of Clinical Oncology</i> , 2019, 37, 316-316.	1.6	1
52	Tenofovir and Entecavir Have Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization. <i>Journal of Liver Cancer</i> , 2019, 19, 128-135.	1.1	1
53	Novel Albumin- and Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1062-1071.	2.3	23
54	Prognostic Role of Liver Stiffness Measurements Using Magnetic Resonance Elastography in Patients with Compensated Chronic Liver Disease. <i>European Radiology</i> , 2018, 28, 3513-3521.	4.5	24

#	ARTICLE	IF	CITATIONS
55	Liver Stiffness Measured by Two-Dimensional Shear-Wave Elastography: Prognostic Value after Radiofrequency Ablation for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 65-75.	7.7	23
56	Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B endemic area. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1490-1501.	3.7	22
57	Low-molecular-weight heparin treatment for portal vein thrombosis in liver cirrhosis: Efficacy and the risk of hemorrhagic complications. <i>Thrombosis Research</i> , 2018, 163, 71-76.	1.7	47
58	A Model for Adaptive Decision Making of "Ablate-and-Wait" Versus Transplantation in Patients With Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 655-661.	2.2	1
59	Effect of longitudinal changes of body fat on the incidence and regression of nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2018, 50, 389-395.	0.9	18
60	Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals. <i>Journal of Viral Hepatitis</i> , 2018, 25, 707-717.	2.0	23
61	Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study. <i>BMC Cancer</i> , 2018, 18, 307.	2.6	18
62	Fully validated SRM-MS-based method for absolute quantification of PIVKA-II in human serum: Clinical applications for patients with HCC. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 156, 142-146.	2.8	9
63	Nonalcoholic fatty liver disease and advanced fibrosis are associated with left ventricular diastolic dysfunction. <i>Atherosclerosis</i> , 2018, 272, 137-144.	0.8	38
64	Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBsAg-positive high viral load chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2018, 25, 552-560.	2.0	11
65	Initial Alpha-Fetoprotein Response Predicts Prognosis in Hepatitis B-related Solitary HCC Patients After Radiofrequency Ablation. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, e18-e26.	2.2	13
66	Is Combination Antiviral Therapy Mandatory for Maintenance Therapy in Fully Suppressed Multidrug-Resistant Hepatitis B Patients?. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-9.	1.5	1
67	Concomitant food intake does not affect the efficacy of entecavir in chronic hepatitis B patients with virological response: a randomized, multicenter, noninferiority trial. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 3767-3774.	4.3	0
68	Analysis of significant protein abundance from multiple reaction-monitoring data. <i>BMC Systems Biology</i> , 2018, 12, 123.	3.0	0
69	Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence. <i>Journal of Korean Medical Science</i> , 2018, 33, e283.	2.5	21
70	Drug response prediction model using a hierarchical structural component modeling method. <i>BMC Bioinformatics</i> , 2018, 19, 288.	2.6	1
71	Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality. <i>Scientific Reports</i> , 2018, 8, 13651.	3.3	7
72	Clinical Assay for AFP-L3 by Using Multiple Reaction Monitoring-Mass Spectrometry for Diagnosing Hepatocellular Carcinoma. <i>Clinical Chemistry</i> , 2018, 64, 1230-1238.	3.2	36

#	ARTICLE	IF	CITATIONS
73	Scoring system for risk stratification of viral reactivation during prophylactic antiviral treatment in Korean patients with hepatitis B undergoing anticancer chemotherapy: A multicenter study. <i>Journal of Medical Virology</i> , 2018, 90, 1593-1603.	5.0	6
74	Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. <i>Journal of Hepatology</i> , 2018, 68, S37-S38.	3.7	6
75	Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib. <i>Cancer Research and Treatment</i> , 2018, 50, 366-373.	3.0	15
76	Targeted Proteomics Predicts a Sustained Complete-Response after Transarterial Chemoembolization and Clinical Outcomes in Patients with Hepatocellular Carcinoma: A Prospective Cohort Study. <i>Journal of Proteome Research</i> , 2017, 16, 1239-1248.	3.7	27
77	Synergistic effect of cytokine-induced killer cell with valproate inhibits growth of hepatocellular carcinoma cell in a mouse model. <i>Cancer Biology and Therapy</i> , 2017, 18, 67-75.	3.4	13
78	Perceived needs for the information communication technology (ICT)-based personalized health management program, and its association with information provision, health-related quality of life (HRQOL), and decisional conflict in cancer patients. <i>Psycho-Oncology</i> , 2017, 26, 1810-1817.	2.3	9
79	A quantitative analytical method for PIVKA-II using multiple reaction monitoring-mass spectrometry for early diagnosis of hepatocellular carcinoma. <i>Analytical and Bioanalytical Chemistry</i> , 2017, 409, 2829-2838.	3.7	9
80	Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. <i>Hepatology</i> , 2017, 66, 855-868.	7.3	35
81	Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment. <i>Hepatology</i> , 2017, 66, 1556-1569.	7.3	92
82	Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS). <i>Molecular and Cellular Proteomics</i> , 2017, 16, 1312-1323.	3.8	25
83	Integrative analysis of genomic and epigenomic regulation of the transcriptome in liver cancer. <i>Nature Communications</i> , 2017, 8, 839.	12.8	107
84	A model to estimate survival in ambulatory patients with hepatocellular carcinoma: Can it predict the natural course of hepatocellular carcinoma?. <i>Digestive and Liver Disease</i> , 2017, 49, 1273-1279.	0.9	5
85	Serum fibronectin distinguishes the early stages of hepatocellular carcinoma. <i>Scientific Reports</i> , 2017, 7, 9449.	3.3	37
86	Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus. <i>European Radiology</i> , 2017, 27, 1448-1458.	4.5	31
87	Identification of novel <i>OCT4</i> genetic variant associated with the risk of chronic hepatitis B in a Korean population. <i>Liver International</i> , 2017, 37, 354-361.	3.9	13
88	Real-time US-CT/MR fusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 66, 347-354.	3.7	103
89	Human Chorionic Plate-Derived Mesenchymal Stem Cells Restore Hepatic Lipid Metabolism in a Rat Model of Bile Duct Ligation. <i>Stem Cells International</i> , 2017, 2017, 1-9.	2.5	9
90	Oral Medications Enhance Adherence to Surveillance for Hepatocellular Carcinoma and Survival in Chronic Hepatitis B Patients. <i>PLoS ONE</i> , 2017, 12, e0166188.	2.5	8

#	ARTICLE	IF	CITATIONS
91	Validation of a Modified Child-Turcotte-Pugh Classification System Utilizing Insulin-Like Growth Factor-1 for Patients with Hepatocellular Carcinoma in an HBV Endemic Area. PLoS ONE, 2017, 12, e0170394.	2.5	11
92	3-bromopyruvate and buthionine sulfoximine effectively kill anoikis-resistant hepatocellular carcinoma cells. PLoS ONE, 2017, 12, e0174271.	2.5	18
93	Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients. Clinical and Molecular Hepatology, 2017, 23, 66-73.	8.9	13
94	Percutaneous Dual-Switching Monopolar Radiofrequency Ablation Using a Separable Clustered Electrode: A Preliminary Study. Korean Journal of Radiology, 2017, 18, 799.	3.4	12
95	Ultrasound-guided percutaneous portal transplantation of peripheral blood monocytes in patients with liver cirrhosis. Korean Journal of Internal Medicine, 2017, 32, 261-268.	1.7	8
96	A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels. Gut and Liver, 2017, 11, 528-534.	2.9	22
97	Cytokine-Induced Killer Cells for the Adjuvant Treatment of Patients with HCC. , 2017, , 69-84.		0
98	Lysophosphatidylcholine. , 2017, , 2605-2607.		0
99	Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria. Oncotarget, 2017, 8, 47555-47564.	1.8	1
100	Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14. PLoS ONE, 2016, 11, e0160822.	2.5	38
101	Transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: Phase 2 trial. Hepatology, 2016, 64, 2185-2197.	7.3	213
102	High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma. Journal of Medical Virology, 2016, 88, 1010-1017.	5.0	50
103	Fucoidan-induced ID-1 suppression inhibits the in vitro and in vivo invasion of hepatocellular carcinoma cells. Biomedicine and Pharmacotherapy, 2016, 83, 607-616.	5.6	30
104	Differential sensitivity of hepatocellular carcinoma cells to suppression of hepatocystin transcription under hypoxic conditions. Journal of Bioenergetics and Biomembranes, 2016, 48, 581-590.	2.3	4
105	TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials. British Journal of Cancer, 2016, 115, 1201-1205.	6.4	19
106	Percutaneous ethanol injection therapy is comparable to radiofrequency ablation in hepatocellular carcinoma smaller than 1.5cm. Medicine (United States), 2016, 95, e4551.	1.0	13
107	Serum Tumor Markers Provide Refined Prognostication in Selecting Liver Transplantation Candidate for Hepatocellular Carcinoma Patients Beyond the Milan Criteria. Annals of Surgery, 2016, 263, 842-850.	4.2	105
108	Hypoxia Enhances Tumor-Stroma Crosstalk that Drives the Progression of Hepatocellular Carcinoma. Digestive Diseases and Sciences, 2016, 61, 2568-2577.	2.3	22

#	ARTICLE	IF	CITATIONS
109	17 $\beta$ -estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling. <i>Biochemical and Biophysical Research Communications</i> , 2016, 473, 1247-1254.	2.1	24
110	Body Fat Distribution and Risk of Incident and Regressed Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 132-138.e4.	4.4	117
111	Switching Monopolar Radiofrequency Ablation Using a Separable Cluster Electrode in Patients with Hepatocellular Carcinoma: A Prospective Study. <i>PLoS ONE</i> , 2016, 11, e0161980.	2.5	14
112	Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B. <i>PLoS ONE</i> , 2016, 11, e0165722.	2.5	33
113	Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 286-291.	8.9	15
114	Combination of Pegylated Interferon and Nucleos(t)ide Therapy: Toward a Cure of Hepatitis B Virus Infection?. <i>Gut and Liver</i> , 2016, 10, 497-498.	2.9	1
115	Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Medicine (United States)</i> , 2015, 94, e2159.	1.0	85
116	Signal transducer and activator of transcription 3 $\alpha$ -mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma. <i>Hepatology</i> , 2015, 62, 1160-1173.	7.3	165
117	Sorafenib inhibits cancer side population cells by targeting c-Jun N-terminal kinase signaling. <i>Molecular Medicine Reports</i> , 2015, 12, 8247-8252.	2.4	7
118	JNK signaling in hepatocarcinoma cells is associated with the side population upon treatment with anticancer drugs. <i>Molecular Medicine Reports</i> , 2015, 11, 263-268.	2.4	4
119	Comparison of the efficacies of entecavir 0.5 and 1.0%mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments. <i>Journal of Medical Virology</i> , 2015, 87, 999-1007.	5.0	0
120	Association of <i><sc>VARS</sc>2</i> polymorphisms with the risk of chronic hepatitis B in a Korean population. <i>Liver International</i> , 2015, 35, 1934-1940.	3.9	21
121	Forns index predicts recurrence and death in patients with hepatitis B-related hepatocellular carcinoma after curative resection. <i>Liver International</i> , 2015, 35, 1992-2000.	3.9	15
122	Efficacy of antiviral prophylaxis in <sc>HB</sc>sAg-negative, anti<sc>HB</sc>c positive patients undergoing hematopoietic stem cell transplantation. <i>Liver International</i> , 2015, 35, 2530-2536.	3.9	24
123	Radioembolization With Yttrium-90 Resin Microspheres in Hepatocellular Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 495-501.	1.3	36
124	Diagnostic and Prognostic Values of Noninvasive Predictors of Portal Hypertension in Patients with Alcoholic Cirrhosis. <i>PLoS ONE</i> , 2015, 10, e0133935.	2.5	36
125	Hepatitis B Virus-Related Glomerulonephritis: Not a Predominant Cause of Proteinuria in Korean Patients with Chronic Hepatitis B. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-6.	1.5	4
126	Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population. <i>World Journal of Gastroenterology</i> , 2015, 21, 6287.	3.3	51



#	ARTICLE	IF	CITATIONS
127	Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implication. <i>World Journal of Biological Chemistry</i> , 2015, 6, 148.	4.3	119
128	Visceral Adipose Tissue Area as an Independent Risk Factor for Elevated Liver Enzyme in Nonalcoholic Fatty Liver Disease. <i>Medicine (United States)</i> , 2015, 94, e573.	1.0	25
129	Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 148, 1383-1391.e6.	1.3	371
130	Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 2037-2045.	2.5	16
131	Hepatoprotective effect of vitamin C on lithocholic acid-induced cholestatic liver injury in Gulo (âˆ™/âˆ™) mice. <i>European Journal of Pharmacology</i> , 2015, 762, 247-255.	3.5	16
132	Reply. <i>Gastroenterology</i> , 2015, 149, 1640-1641.	1.3	0
133	Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43. <i>Acta Pharmaceutica Sinica B</i> , 2015, 5, 544-553.	12.0	36
134	The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in <sc>A</sc>sian patients with hepatocellular carcinoma: Final results of the <sc>START</sc> trial. <i>International Journal of Cancer</i> , 2015, 136, 1458-1467.	5.1	109
135	Barcelona Clinic Liver Cancer staging system and survival of untreated hepatocellular carcinoma in a hepatitis B virus endemic area. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 696-705.	2.8	13
136	The effect of therapeutic vaccination for the treatment of chronic hepatitis B virus infection. <i>Journal of Medical Virology</i> , 2015, 87, 575-582.	5.0	14
137	Transarterial Chemoembolization for Hepatocellular Carcinomas with Central Bile Duct Invasion: Safety, Prognosis, and Predictive Factors. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 937-945.	2.0	7
138	Comparison of Transarterial Chemoembolization and Hepatic Resection for Large Solitary Hepatocellular Carcinoma: A Propensity Score Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 651-659.	0.5	32
139	Nonalcoholic fatty liver disease is associated with coronary artery calcium score in diabetes patients with higher HbA1c. <i>Diabetology and Metabolic Syndrome</i> , 2015, 7, 28.	2.7	16
140	<sc>CLIF</sc>â€<sc>SOFA</sc> scoring system accurately predicts shortâ€term mortality in acutely decompensated patients with alcoholic cirrhosis: a retrospective analysis. <i>Liver International</i> , 2015, 35, 46-57.	3.9	55
141	Tenofovir Monotherapy versus Tenofovir plus Lamivudine or Telbivudine Combination Therapy in Treatment of Lamivudine-Resistant Chronic Hepatitis B. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 972-978.	3.2	20
142	Role of physical activity in nonalcoholic fatty liver disease in terms of visceral obesity and insulin resistance. <i>Liver International</i> , 2015, 35, 944-952.	3.9	49
143	Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients. <i>PLoS ONE</i> , 2015, 10, e0130392.	2.5	8
144	Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 358.	8.9	12

#	ARTICLE	IF	CITATIONS
145	Spontaneous Evolution in Bilirubin Levels Predicts Liver-Related Mortality in Patients with Alcoholic Hepatitis. <i>PLoS ONE</i> , 2014, 9, e100870.	2.5	18
146	Does 18F-FDG Positron Emission Tomography-Computed Tomography Have a Role in Initial Staging of Hepatocellular Carcinoma?. <i>PLoS ONE</i> , 2014, 9, e105679.	2.5	43
147	Measurement of Glycosylated Alpha-Fetoprotein Improves Diagnostic Power over the Native Form in Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2014, 9, e110366.	2.5	13
148	Small Single-Nodule Hepatocellular Carcinoma: Comparison of Transarterial Chemoembolization, Radiofrequency Ablation, and Hepatic Resection by Using Inverse Probability Weighting. <i>Radiology</i> , 2014, 271, 909-918.	7.3	97
149	Nonalcoholic fatty liver disease is a negative risk factor for prostate cancer recurrence. <i>Endocrine-Related Cancer</i> , 2014, 21, 343-353.	3.1	20
150	A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 5976-5985.	7.0	95
151	MicroRNA-196 polymorphisms and hepatocellular carcinoma in patients with chronic hepatitis B. <i>Journal of Medical Virology</i> , 2014, 86, 446-453.	5.0	19
152	High-sensitivity C-reactive Protein Level is an Independent Predictor of Poor Prognosis in Cirrhotic Patients With Spontaneous Bacterial Peritonitis. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 444-449.	2.2	20
153	Prior Exposure to Lamivudine Increases Entecavir Resistance Risk in Chronic Hepatitis B Patients without Detectable Lamivudine Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1730-1737.	3.2	28
154	Sodium taurocholate cotransporting polypeptide mediates dual actions of deoxycholic acid in human hepatocellular carcinoma cells: enhanced apoptosis versus growth stimulation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 133-144.	2.5	12
155	Spontaneous fungal peritonitis: a severe complication in patients with advanced liver cirrhosis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2014, 33, 259-264.	2.9	78
156	Mortality associated with proton pump inhibitors in cirrhotic patients with spontaneous bacterial peritonitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 775-781.	2.8	59
157	Efficacy of Entecavir-Tenofovir Combination Therapy for Chronic Hepatitis B Patients with Multidrug-Resistant Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6710-6716.	3.2	32
158	Tauroursodeoxycholic Acid Attenuates Progression of Steatohepatitis in Mice Fed a Methionine-Choline-Deficient Diet. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1461-1474.	2.3	37
159	Relationship between polymorphisms near the IL28B gene and spontaneous HBsAg seroclearance: a systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , 2014, 21, 163-170.	2.0	16
160	Serum Insulin-Like Growth Factor-1 Predicts Disease Progression and Survival in Patients with Hepatocellular Carcinoma Who Undergo Transarterial Chemoembolization. <i>PLoS ONE</i> , 2014, 9, e90862.	2.5	11
161	Comparison of the Effects of Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma between Patients with and without Extrahepatic Metastases. <i>PLoS ONE</i> , 2014, 9, e113926.	2.5	17
162	A novel prognostic factor for hepatocellular carcinoma: protein disulfide isomerase. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 580.	1.7	16

#	ARTICLE	IF	CITATIONS
163	Pathologically Confirmed Spontaneous Partial Regression of Hepatocellular Carcinoma. Korean Journal of Medicine, 2014, 86, 198.	0.3	1
164	Development and validation of a scoring system using insulin-like growth factor to assess hepatic reserve in hepatocellular carcinoma.. Journal of Clinical Oncology, 2014, 32, 231-231.	1.6	0
165	Lysophosphatidylcholine. , 2014, , 1-3.		0
166	Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization. Journal of Cancer Research and Clinical Oncology, 2013, 139, 635-643.	2.5	32
167	Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin. Journal of Gastroenterology, 2013, 48, 1401-1410.	5.1	35
168	Excellent Outcome in 238 Consecutive Living Donor Liver Transplantations Using the Right Liver Graft in a Large Volume Single Center. World Journal of Surgery, 2013, 37, 1419-1429.	1.6	21
169	Transarterial Chemoembolization with Additional Cisplatin Infusion for Hepatocellular Carcinoma Invading the Hepatic Vein. Journal of Vascular and Interventional Radiology, 2013, 24, 274-283.	0.5	42
170	The Efficacy of Adefovir Plus Entecavir Combination Therapy in Patients with Chronic Hepatitis B Refractory to Both Lamivudine and Adefovir. Digestive Diseases and Sciences, 2013, 58, 1363-1370.	2.3	6
171	Molecular targeted therapy with transarterial chemoembolization. Gastrointestinal Intervention, 2013, 2, 78-81.	0.1	1
172	Hepatocellular Carcinoma: High Hepatitis B Viral Load and Mortality in Patients Treated with Transarterial Chemoembolization. Radiology, 2013, 267, 638-647.	7.3	28
173	A genome-wide association study identified new variants associated with the risk of chronic hepatitis B. Human Molecular Genetics, 2013, 22, 4233-4238.	2.9	105
174	Serum Insulin-like Growth Factor-I Level Is an Independent Predictor of Recurrence and Survival in Early Hepatocellular Carcinoma: A Prospective Cohort Study. Clinical Cancer Research, 2013, 19, 4218-4227.	7.0	28
175	Efficacy of Adefovir-Based Combination Therapy for Patients with Lamivudine- and Entecavir-Resistant Chronic Hepatitis B Virus Infection. Antimicrobial Agents and Chemotherapy, 2013, 57, 6325-6332.	3.2	13
176	Guggulsterone attenuates activation and survival of hepatic stellate cell by inhibiting nuclear factor kappa B activation and inducing apoptosis. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1859-1868.	2.8	15
177	Polymorphisms near Interleukin 28B Gene Are Not Associated with Hepatitis B Virus Clearance, Hepatitis B e Antigen Clearance and Hepatocellular Carcinoma Occurrence. Intervirology, 2013, 56, 84-90.	2.8	27
178	Interim analysis of START: Study in asia of the combination of TACE (transcatheter arterial) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 147 Td Journal of Cancer, 2013, 132, 2448-2458.	5.1	81
179	Noninvasive fibrosis indices predict intrahepatic distant recurrence of hepatitis B-related hepatocellular carcinoma following radiofrequency ablation. Liver International, 2013, 33, 884-893.	3.9	19
180	Development of Biomarkers for Screening Hepatocellular Carcinoma Using Global Data Mining and Multiple Reaction Monitoring. PLoS ONE, 2013, 8, e63468.	2.5	30

#	ARTICLE	IF	CITATIONS
181	Efficacy of thymosin $\alpha$ -1 plus peginterferon $\alpha$ -2a combination therapy compared with peginterferon $\alpha$ -2a monotherapy in HBeAg-positive chronic hepatitis B: A prospective, multicenter, randomized, open-label study. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 1048-1055.	1.5	19
182	Clinical Prediction of Failure of Lamivudine Prophylaxis for Hepatitis B Virus-Infected Patients Undergoing Cytotoxic Chemotherapy for Malignancy. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5511-5519.	3.2	15
183	Simple Scoring System Predicting Genotypic Resistance During Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 243-250.	2.2	4
184	Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. <i>Journal of Hepatology</i> , 2012, 57, 150-156.	3.7	234
185	STAT3 & Cytochrome P450 2C9: A novel signaling pathway in liver cancer stem cells. <i>Biomedicine and Pharmacotherapy</i> , 2012, 66, 612-616.	5.6	18
186	Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2012, 18, 383.	8.9	96
187	Percutaneous Radiofrequency Ablation with Multiple Electrodes for Medium-Sized Hepatocellular Carcinomas. <i>Korean Journal of Radiology</i> , 2012, 13, 34.	3.4	57
188	Nonalcoholic fatty liver disease is associated with coronary artery calcification. <i>Hepatology</i> , 2012, 56, 605-613.	7.3	259
189	Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting ER stress and anti-angiogenesis by protein disulfide isomerase inhibition. <i>Journal of Bioenergetics and Biomembranes</i> , 2012, 44, 101-115.	2.3	39
190	Prognostic implications of tumor vascularity and its relationship to cytokeratin 19 expression in patients with hepatocellular carcinoma. <i>Abdominal Imaging</i> , 2012, 37, 439-446.	2.0	19
191	Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance. <i>Journal of Medical Virology</i> , 2012, 84, 424-430.	5.0	16
192	Risk Factors, Clinical Features, and Prognosis of the Hepatocellular Carcinoma with Peritoneal Metastasis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 813-819.	2.3	31
193	A phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4103-4103.	1.6	6
194	Association of Polymorphism in Pri-microRNAs-371-372-373 with the Occurrence of Hepatocellular Carcinoma in Hepatitis B Virus Infected Patients. <i>PLoS ONE</i> , 2012, 7, e41983.	2.5	23
195	Mesalamine-induced B7 $\alpha$ expression on hepatic stellate cells attenuates autoimmune liver injury. <i>Hepatology Research</i> , 2011, 41, 79-86.	3.4	4
196	Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2011, 47, 2117-2127.	2.8	496
197	Validation of P2/MS and Other Noninvasive Fibrosis Scoring Systems in the Korean Population with Nonalcoholic Fatty Liver Disease. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2011, 57, 19.	0.4	10
198	Treatment and clinical outcome of needle-track seeding from hepatocellular carcinoma. <i>The Korean Journal of Hepatology</i> , 2011, 17, 106.	1.5	22

#	ARTICLE	IF	CITATIONS
199	Ursodeoxycholic acid-induced inhibition of DLC1 protein degradation leads to suppression of hepatocellular carcinoma cell growth. <i>Oncology Reports</i> , 2011, 25, 1739-46.	2.6	17
200	Why, When, and How to Prevent Hepatitis B Virus Reactivation in Cancer Patients Undergoing Chemotherapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 465-477.	4.9	24
201	Long-term Prognosis of Combined Hepatocellular and Cholangiocarcinoma After Curative Resection Comparison With Hepatocellular Carcinoma and Cholangiocarcinoma. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 69-75.	2.2	130
202	Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1638-1645.	2.8	17
203	Add-On Adefovir Is Superior to a Switch to Entecavir as Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2130-2136.	2.3	31
204	Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation. <i>BMC Cancer</i> , 2011, 11, 435.	2.6	22
205	Serum HBsAg levels during peginterferon $\alpha$ 2a treatment with or without thymosin $\alpha$ 1 in HBeAg-positive chronic hepatitis B patients. <i>Journal of Medical Virology</i> , 2011, 83, 88-94.	5.0	11
206	Transarterial Chemoembolization Can Be Safely Performed in Patients with Hepatocellular Carcinoma Invading the Main Portal Vein and May Improve the Overall Survival. <i>Radiology</i> , 2011, 258, 627-634.	7.3	264
207	Inhibition of hypoxia-inducible carbonic anhydrase-IX enhances hexokinase II inhibitor-induced hepatocellular carcinoma cell apoptosis. <i>Acta Pharmacologica Sinica</i> , 2011, 32, 912-920.	6.1	35
208	Relative Etiological Role of Prior Hepatitis B Virus Infection and Nonalcoholic Fatty Liver Disease in the Development of Non-B Non-C Hepatocellular Carcinoma in a Hepatitis B-Endemic Area. <i>Digestion</i> , 2011, 84, 17-22.	2.3	57
209	Predictors of HBsAg Seroclearance in HBeAg-Negative Chronic Hepatitis B Patients. <i>Digestion</i> , 2011, 84, 23-28.	2.3	13
210	Lysophosphatidylcholine. , 2011, , 2127-2128.		1
211	High Viremia, Prolonged Lamivudine Therapy and Recurrent Hepatocellular Carcinoma Predict Posttransplant Hepatitis B Recurrence. <i>American Journal of Transplantation</i> , 2010, 10, 1658-1668.	4.7	49
212	Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis. <i>Journal of Infection</i> , 2010, 61, 323-329.	3.3	32
213	CT Findings of Completely Regressed Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombosis after Transcatheter Arterial Chemoembolization. <i>Korean Journal of Radiology</i> , 2010, 11, 69.	3.4	3
214	Synergistic antifibrotic efficacy of statin and protein kinase C inhibitor in hepatic fibrosis. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 298, G126-G132.	3.4	27
215	Caudate Lobe Hepatocellular Carcinoma Treated with Selective Chemoembolization. <i>Radiology</i> , 2010, 257, 278-287.	7.3	32
216	Identification of a Cholangiocarcinoma-Like Gene Expression Trait in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2010, 70, 3034-3041.	0.9	166

#	ARTICLE	IF	CITATIONS
217	Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2010, 42, 503-508.	0.9	896
218	Role of surgical resection for pulmonary metastasis of hepatocellular carcinoma. <i>Lung Cancer</i> , 2010, 70, 295-300.	2.0	33
219	Retinoic acid and its binding protein modulate apoptotic signals in hypoxic hepatocellular carcinoma cells. <i>Cancer Letters</i> , 2010, 295, 229-235.	7.2	11
220	Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells. <i>Cancer Letters</i> , 2010, 298, 9-15.	7.2	49
221	Validation of P2/MS for reflecting hepatic fibrosis in patients with hepatocellular carcinoma. <i>The Korean Journal of Hepatology</i> , 2010, 16, 389.	1.5	2
222	The Relation Between Non-Alcoholic Fatty Liver Disease and the Risk of Coronary Heart Disease in Koreans. <i>American Journal of Gastroenterology</i> , 2009, 104, 1953-1960.	0.4	117
223	Heat Shock Protein 90 Inhibitor Induces Apoptosis and Attenuates Activation of Hepatic Stellate Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 330, 276-282.	2.5	41
224	Improved outcome of adult recipients with a high model for end-stage liver disease score and a small-for-size graft. <i>Liver Transplantation</i> , 2009, 15, 496-503.	2.4	61
225	Enterococcus: not an innocent bystander in cirrhotic patients with spontaneous bacterial peritonitis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2009, 28, 21-26.	2.9	18
226	Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 497-507.	2.3	28
227	Complete blood count reflects the degree of oesophageal varices and liver fibrosis in virus-related chronic liver disease patients. <i>Journal of Viral Hepatitis</i> , 2009, 16, 444-452.	2.0	21
228	Putative association of transforming growth factor- $\beta$ polymorphisms with clearance of hepatitis B virus and occurrence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. <i>Journal of Viral Hepatitis</i> , 2009, 17, 518-26.	2.0	18
229	Clinical features of acute renal failure associated with hepatitis A virus infection. <i>Journal of Viral Hepatitis</i> , 2009, 17, 611-7.	2.0	21
230	Enhanced interleukin-2 diphtheria toxin conjugate-induced growth suppression in retinoic acid-treated hypoxic hepatocellular carcinoma cells. <i>Cancer Letters</i> , 2009, 274, 259-265.	7.2	6
231	The prevalence of hepatitis B virus preS deletions occurring naturally in Korean patients infected chronically with genotype C. <i>Journal of Medical Virology</i> , 2008, 80, 1189-1194.	5.0	67
232	Hepatitis B virus X mutations occurring naturally associated with clinical severity of liver disease among Korean patients with chronic genotype C infection. <i>Journal of Medical Virology</i> , 2008, 80, 1337-1343.	5.0	45
233	Hypoxia-inducible adrenomedullin accelerates hepatocellular carcinoma cell growth. <i>Cancer Letters</i> , 2008, 271, 314-322.	7.2	27
234	Gene Expression-Based Recurrence Prediction of Hepatitis B Virus-Related Human Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 2056-2064.	7.0	157

#	ARTICLE	IF	CITATIONS
235	Experimental Agents Which Inhibit Hepatocarcinogenesis. <i>Oncology</i> , 2008, 75, 17-21.	1.9	30
236	Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2554-2562.	4.1	100
237	SPP1 polymorphisms associated with HBV clearance and HCC occurrence. <i>International Journal of Epidemiology</i> , 2007, 36, 1001-1008.	1.9	57
238	Molecular Epidemiology of Hepatitis B Virus (HBV) Genotypes and Serotypes in Patients with Chronic HBV Infection in Korea. <i>Intervirology</i> , 2007, 50, 52-57.	2.8	110
239	Characterization of Two Hepatitis B Virus Populations in a Single Korean Hepatocellular Carcinoma Patient with an HBeAg-Negative Serostatus: A Novel X-Gene-Deleted Strain with Inverted Duplication Sequences of Upstream Enhancer Site II. <i>Intervirology</i> , 2007, 50, 273-280.	2.8	14
240	Bile acid-mediated thrombospondin-1 induction in hepatocytes leads to transforming growth factor- $\beta$ -dependent hepatic stellate cell activation. <i>Biochemical and Biophysical Research Communications</i> , 2007, 353, 1091-1096.	2.1	21
241	Bile acid-induced TGR5-dependent c-Jun-N terminal kinase activation leads to enhanced caspase 8 activation in hepatocytes. <i>Biochemical and Biophysical Research Communications</i> , 2007, 361, 156-161.	2.1	58
242	Wnt signaling enhances the activation and survival of human hepatic stellate cells. <i>FEBS Letters</i> , 2007, 581, 2954-2958.	2.8	77
243	HDAC10 promoter polymorphism associated with development of HCC among chronic HBV patients. <i>Biochemical and Biophysical Research Communications</i> , 2007, 363, 776-781.	2.1	35
244	Analysis of hepatitis B virus quasispecies distribution in a Korean chronic patient based on the full genome sequences. <i>Journal of Medical Virology</i> , 2007, 79, 212-219.	5.0	29
245	Do young hepatocellular carcinoma patients with relatively good liver function have poorer outcomes than elderly patients?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1226-1231.	2.8	66
246	Bile acid-mediated induction of cyclooxygenase-2 and Mcl-1 in hepatic stellate cells. <i>Biochemical and Biophysical Research Communications</i> , 2006, 342, 1108-1113.	2.1	10
247	IGF2 polymorphisms are associated with hepatitis B virus clearance and hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2006, 346, 38-44.	2.1	26
248	Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma: Prevalence and Causative Factors of Extrahepatic Collateral Arteries in 479 Patients. <i>Korean Journal of Radiology</i> , 2006, 7, 257.	3.4	85
249	Eupatilin attenuates bile acid-induced hepatocyte apoptosis. <i>Journal of Gastroenterology</i> , 2006, 41, 772-778.	5.1	29
250	Lysophosphatidylcholine suppresses apoptotic cell death by inducing cyclooxygenase-2 expression via a Raf-1 dependent mechanism in human cholangiocytes. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006, 132, 771-779.	2.5	15
251	Anti-apoptotic N-cadherin signaling and its prognostic implication in human hepatocellular carcinomas. <i>Oncology Reports</i> , 2006, 15, 1117-23.	2.6	15
252	Diffuse infiltrative hepatocellular carcinomas in a hepatitis B-endemic area: diagnostic and therapeutic impediments. <i>Hepato-Gastroenterology</i> , 2006, 53, 266-70.	0.5	16

#	ARTICLE	IF	CITATIONS
253	Prevalence of naturally occurring surface antigen variants of hepatitis B virus in Korean patients infected chronically. <i>Journal of Medical Virology</i> , 2005, 76, 194-202.	5.0	94
254	Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005, 131, 649-652.	2.5	100
255	Augmentation of Butyrate-induced Differentiation of Human Hepatocyte by Cyclin E Over-expression. <i>International Journal of Artificial Organs</i> , 2005, 28, 44-50.	1.4	2
256	Population Genotyping of Hepatitis C Virus by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Analysis of Short DNA Fragments. <i>Clinical Chemistry</i> , 2005, 51, 1123-1131.	3.2	48
257	Prediction of Treatment Outcome in Chronic Hepatitis C Patients Based on Early Viral Dynamics during High-Dose Induction Interferon and Ribavirin Therapy. <i>Intervirology</i> , 2005, 48, 230-238.	2.8	8
258	Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. <i>Journal of Hepatology</i> , 2005, 42, 358-364.	3.7	164
259	15d-Deoxy- $\gamma$ -12,14-prostaglandin J2 modulates collagen type I synthesis in human hepatic stellate cells by inducing oxidative stress. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2005, 73, 361-367.	2.2	6
260	Imatinib mesylate induces apoptosis in human cholangiocarcinoma cells. <i>Liver International</i> , 2004, 24, 687-695.	3.9	22
261	Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: Implications for biliary tract carcinogenesis. <i>Hepatology</i> , 2004, 39, 732-738.	7.3	83
262	Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. <i>Journal of Hepatology</i> , 2004, 41, 808-814.	3.7	117
263	Diagnosis, staging, and treatment of cholangiocarcinoma. <i>Current Treatment Options in Gastroenterology</i> , 2003, 6, 105-112.	0.8	20
264	Association of TNF- $\alpha$ promoter polymorphisms with the clearance of hepatitis B virus infection. <i>Human Molecular Genetics</i> , 2003, 12, 2541-2546.	2.9	132
265	Association of transforming growth factor- $\beta$ 1 gene polymorphisms with a hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. <i>Experimental and Molecular Medicine</i> , 2003, 35, 196-202.	7.7	74
266	Bile Acids Stimulate cFLIP Phosphorylation Enhancing TRAIL-mediated Apoptosis. <i>Journal of Biological Chemistry</i> , 2003, 278, 454-461.	3.4	102
267	Bile acids activate EGF receptor via a TGF- $\beta$ -dependent mechanism in human cholangiocyte cell lines. <i>American Journal of Physiology - Renal Physiology</i> , 2003, 285, G31-G36.	3.4	134
268	Therapeutic Efficacy of Transcatheter Arterial Chemoembolization as Compared With Hepatic Resection in Hepatocellular Carcinoma Patients With Compensated Liver Function in a Hepatitis B Virus-Endemic Area: A Prospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2002, 20, 4459-4465.	1.6	106
269	Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. <i>Gastroenterology</i> , 2002, 122, 985-993.	1.3	166
270	Death receptor-mediated apoptosis and the liver. <i>Journal of Hepatology</i> , 2002, 37, 400-410.	3.7	173



#	ARTICLE	IF	CITATIONS
271	Monitoring of transtubular potassium gradient in the diuretic management of patients with cirrhosis and ascites. <i>Liver</i> , 2002, 22, 426-432.	0.1	8
272	Modulation of cytokeratin expression during in vitro cultivation of human hepatic stellate cells: evidence of transdifferentiation from epithelial to mesenchymal phenotype. <i>Histochemistry and Cell Biology</i> , 2002, 118, 127-136.	1.7	34
273	COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. <i>Hepatology</i> , 2002, 35, 552-559.	7.3	141
274	Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. <i>Cancer Research</i> , 2002, 62, 6500-5.	0.9	72
275	Recurrent hepatocellular carcinoma after spontaneous regression. <i>Journal of Gastroenterology</i> , 2000, 35, 552-556.	5.1	23
276	Augmentation of urea-synthetic capacity by inhibition of nitric oxide synthesis in butyrate-induced differentiated human hepatocytes. <i>FEBS Letters</i> , 2000, 474, 175-178.	2.8	11
277	Development of a Non-Transformed Human Liver Cell Line with Differentiated-Hepatocyte and Urea-Synthetic Functions: Applicable for Bioartificial Liver. <i>International Journal of Artificial Organs</i> , 1999, 22, 769-777.	1.4	41
278	Anti-apoptotic N-cadherin signaling and its prognostic implication in human hepatocellular carcinomas. <i>Oncology Reports</i> , 0, , .	2.6	8